Gendel

United Kingdom
Coleraine, Northern Ireland, United Kingdom, BT52 1ST

Company profile

Gendel company profile

Gendel has developed a unique, proprietary platform technology for the localised delivery of biological molecules to target sites within the body. Biopharmaceuticals may be loaded into the body's own natural carrier system by a physical process and released at the target site in response to the application of non-invasive, low intensity ultrasound. Gendel's technology may be employed for the delivery of a range of biological payloads including antibodies, enzymes, peptides, olionucleotides and DNA as well as carrier peptides and gene therapy vectors.

Business identity

Operating status
Closed
Company type
For Profit
Founded
1998-01-01, Year

Headquarters

Postal code
BT52 1ST
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
3
Total equity funding
$3.3M
Last funding
Series Unknown / $366,000 / 2005-05-25
Last equity funding
Series Unknown / $366,000
Investors
4
Lead investors
1
Founders
1
Articles
1
Closed on
2012-05-09

Founders and investors

Founders

Les Russell

Lead investors

Crescent Capital

Investors

Crescent CapitalEnterprise EquityInvest Northern IrelandScottish Equity Partners